Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer

DOI QR Code

Lim, Jeong Uk (Division of Hematology and Oncology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
Woo, In Sook (Division of Hematology and Oncology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
Jung, Yun Hwa (Division of Hematology and Oncology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
Byeon, Jae Ho (Division of Hematology and Oncology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
Park, Chan Kwon (Division of Pulmonology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
Kim, Tae Jung (Department of Hospital Pathology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
Kim, Hyo Rim (Department of Radiology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea)

Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013;31:1070-1080. https://doi.org/10.1200/JCO.2012.43.3912
Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
Zakowski MF, Ladanyi M, Kris MG; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006;355:213-215. https://doi.org/10.1056/NEJMc053610
Popat S, Wotherspoon A, Nutting CM, Gonzalez D, Nicholson AG, O'Brien M. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer 2013;80:1-4. https://doi.org/10.1016/j.lungcan.2012.12.019
Yanagisawa S, Morikawa N, Kimura Y, Nagano Y, Murakami K, Tabata T. Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma. Respirology 2012;17:1275-1277. https://doi.org/10.1111/j.1440-1843.2012.02258.x

Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells vol.6, pp.30, 2015, https://doi.org/10.18632/oncotarget.5022
Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4 vol.7, pp.2, 2014, https://doi.org/10.18632/oncotarget.6451
MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance vol.8, pp.1, 2017, https://doi.org/10.1038/s41467-017-01967-6
Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors vol.23, pp.2, 2018, https://doi.org/10.1007/s10147-017-1211-1
Role of Cytomorphology in the Era of Liquid Biopsy vol.63, pp.6, 2014, https://doi.org/10.1159/000499338
pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma vol.2, pp.1, 2014, https://doi.org/10.1038/s42003-019-0572-6
Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases vol.9, pp.18, 2021, https://doi.org/10.12998/wjcc.v9.i18.4617